abstract |
The present disclosure provides an anti-CD70 antibody, an antigen-binding fragment thereof, a chimeric antigen receptor (CAR), and an engineered T cell receptor (TCR) comprising an antigen-binding molecule that specifically binds to CD70, encoding a multinuclear Glycosylates and in vitro cells containing them. The polynucleotides, polypeptides, and in vitro cells described herein can be used in engineered TCR and/or CAR T cell therapy for treating patients suffering from cancer. In a specific embodiment, the polynucleotides, polypeptides, and in vitro cells described herein are useful for treating multiple myeloma. |